Adolore Biotherapeutics, Inc. | WebDisclosure

Basculer en Français

10621	Companies
225714	Keywords
154268	Articles
119432	Press releases

Headlines Articles Press releases Adolore Biotherapeutics, Inc.

Home
Companies
Adolore Biotherapeutics, Inc.

PRESS RELEASE

published on 05/16/2024 at 16:00, 2 years 1 month ago

Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies

Adolore BioTherapeutics Chronic Pain Gene Therapy Non-opioid Analgesics IND-enabling Studies
BRIEF

published on 03/04/2024 at 16:05, 2 years 3 months ago

Adolore BioTherapeutics obtient un brevet américain pour la thérapie génique CA8* dans le traitement de la douleur chronique

Adolore BioTherapeutics Thérapie Génique Traitement De La Douleur Chronique Solutions Sans Opioïdes Délivrance De Brevet
BRIEF

published on 03/04/2024 at 16:05, 2 years 3 months ago

Adolore BioTherapeutics Secures U.S. Patent for CA8* Gene Therapy in Chronic Pain Treatment

Adolore BioTherapeutics Gene Therapy Chronic Pain Treatment Opioid-Free Solutions Patent Issuance
PRESS RELEASE

published on 03/04/2024 at 16:00, 2 years 3 months ago

Adolore BioTherapeutics Announces Issuance of First U.S. Patent Covering CA8* Gene Therapies to Treat Chronic Pain
Adolore BioTherapeutics licenses patent and CA8* gene therapy technology from the University of Miami for opioid-free chronic pain treatment. Company progresses toward clinical testing and commercialization

University Of Miami Adolore BioTherapeutics Chronic Pain Opioid-free Gene Therapy
PRESS RELEASE

published on 01/30/2024 at 16:00, 2 years 4 months ago

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting
Adolore BioTherapeutics will present at the 5th Annual NIH HEAL Initiative Scientific Meeting regarding the gene therapy program for chronic pain associated with knee osteoarthritis. The program is supported by NIH/NINDS HEAL UH3 Award

Adolore BioTherapeutics Chronic Pain NIH HEAL Initiative Gene Therapy Osteoarthritis
PRESS RELEASE

published on 12/05/2023 at 16:30, 2 years 6 months ago

Adolore BioTherapeutics Presents Promising Preclinical Data Supporting Its Innovative Gene Therapy to Treat Chronic Pain
Adolore BioTherapeutics presented preclinical data supporting its innovative CA8* gene therapy as a long-acting local analgesic for chronic osteoarthritis knee pain management, aiming to replace opioids

Adolore BioTherapeutics CA8* Gene Therapy Chronic Pain Opioid-free Preclinical Data
PRESS RELEASE

published on 10/11/2023 at 16:00, 2 years 8 months ago

Adolore BioTherapeutics to Participate at the Virtual Investor Ask the CEO Conference
PRESS RELEASE

published on 10/03/2023 at 15:15, 2 years 8 months ago

NIN/NINDS HEAL Program Grants Prestigious UH3 Award to the University of Miami, Principal Investigator Roy C. Levitt M.D, to Fund Clinical Development of Adolore BioTherapeutics’ Gene Therapy Program for the Treatment of Chronic Osteoarthritis Knee Pain

Accesswire

Published on 06/24/2026 at 03:15, 3 hours 38 minutes ago

Noram Lithium Adopts Semi-Annual Financial Reporting
Published on 06/24/2026 at 00:00, 6 hours 53 minutes ago

Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
Published on 06/23/2026 at 23:45, 7 hours 8 minutes ago

Prospect Ridge Aligns with the Market Mindset for Exclusive Live Investor Interview Discussing Game-changing 2026 Drill Programs
Published on 06/23/2026 at 23:20, 7 hours 33 minutes ago

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Published on 06/23/2026 at 23:15, 7 hours 38 minutes ago

EV Nickel Signs LOI Forming High-Grade Nickel Joint Venture for Shaw Dome Projects

View all ACCESSWIRE

EQS Group

Published on 06/24/2026 at 05:55, 58 minutes ago

Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026
Published on 06/24/2026 at 04:00, 2 hours 53 minutes ago

Shipping edges closer to onboard carbon mineralisation as IMO endorses Shanghai Qiyao Technology Group Co., Ltd. proposals
Published on 06/24/2026 at 02:05, 4 hours 48 minutes ago

FRONTERA AND KUPARI ANNOUNCE COMMENCEMENT OF STRATEGIC SALE PROCESS FOR THE JOINTLY OWNED PIEDRAS VERDES COPPER MINE COMPLEX IN SONORA, MEXICO
Published on 06/23/2026 at 22:20, 8 hours 33 minutes ago

Saudi Properties Portal to Accept Applications for Foreign Real Estate Ownership
Published on 06/23/2026 at 20:15, 10 hours 38 minutes ago

EQS-Adhoc: OHB SE resolves on the issue of 1,605,388 new shares representing the first tranche of the up to 8.86% capital increase with subscription rights

Les Echos

Published on 06/23/2026 at 19:47, 11 hours 5 minutes ago

GROUPE SFPI: reorganisation de la Direction Générale
Published on 06/23/2026 at 19:47, 11 hours 5 minutes ago

GROUPE SFPI: General management reorganisation
Published on 06/23/2026 at 19:10, 11 hours 43 minutes ago

GUILLEMOT CORPORATION > EVOLUTION DE LA GOUVERNANCE A COMPTER DU 23 JUIN 2026
Published on 06/23/2026 at 19:10, 11 hours 43 minutes ago

GUILLEMOT CORPORATION: Changes to Corporate Governance Effective June 23, 2026
Published on 06/23/2026 at 18:32, 12 hours 20 minutes ago

Communiqué sur la demande de radiation auprès d'Euroclear des Droits à Complément de Prix

View all LES ECHOS COMFI WIRE